SebZz
2021-12-03
Nice
Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":601607958,"tweetId":"601607958","gmtCreate":1638517719122,"gmtModify":1638517719122,"author":{"id":3571302905057300,"idStr":"3571302905057300","authorId":3571302905057300,"authorIdStr":"3571302905057300","name":"SebZz","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/601607958","repostId":1138290638,"repostType":4,"repost":{"id":"1138290638","kind":"news","pubTimestamp":1638515006,"share":"https://www.laohu8.com/m/news/1138290638?lang=zh_CN&edition=full","pubTime":"2021-12-03 15:03","market":"us","language":"en","title":"Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138290638","media":"TheStreet","summary":"Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since ","content":"<p>Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.</p><p><blockquote>过去几个月，Clover Health的股票一直在苦苦挣扎。随着CLOV的“模因”势头消退，股价自6月初的峰值以来已下跌80%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/528f59c934a300195181e1a4f4dda4a0\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Clover Health logo.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：三叶草健康标志。</span></p></blockquote></p><p> Now, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.</p><p><blockquote>现在，CLOV已触底，股价跌至不到5美元的历史低点。下面，我们列出了一些问题，可以帮助确定现在是否是投资该股票的时候。</blockquote></p><p> <b>The success of Clover Assistant</b></p><p><blockquote><b>三叶草助手的成功</b></blockquote></p><p> AI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.</p><p><blockquote>AI软件平台Clover Assistant是Clover独特模型中的关键差异化因素，它管理着近10万条生命。该平台旨在帮助医生改善服务并吸引新会员。</blockquote></p><p> Clover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.</p><p><blockquote>Clover的商业模式严重依赖于该平台，但专家们对它能否实现其承诺表示怀疑：医生的易用性和患者的省钱机会。Clover Assistant同比增长223%，第三季度约有2,900名医疗保健专业人员使用Clover Assistant，同比增长45%。</blockquote></p><p> <b>Are bears right?</b></p><p><blockquote><b>熊是对的吗？</b></blockquote></p><p> Known as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.</p><p><blockquote>被称为“SPAC之王”的Clover今年早些时候股价暴跌。可能的罪魁祸首：研究公司兴登堡做空该股票，声称该公司因可疑销售行为而成为调查目标。</blockquote></p><p> After Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.</p><p><blockquote>兴登堡下注后，截至5月底，CLOV股价今年迄今暴跌50%。当时，该股引起了华尔街赌注“猿”社区的注意，并成为模因狂热的目标。自6月初以来，股市飙升190%，但随后下跌约80%至历史低点。</blockquote></p><p> Venture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.</p><p><blockquote>帮助Clover通过SPAC上市的风险投资家Chamath Palihapitiya为该公司的指控进行了辩护。但那时，可能已经太晚了：对CLOV的怀疑已经广泛蔓延，该股成为卖空者的最爱。</blockquote></p><p> Currently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.</p><p><blockquote>目前，空头兴趣有点偏热：根据雅虎财经的数据，目前12%的流通量被做空。我们倾向于认为任何高于10%的指标都是看跌指标和潜在的轧空候选指标。</blockquote></p><p> <b>CLOV’s path to profitability</b></p><p><blockquote><b>CLOV的盈利之路</b></blockquote></p><p> Clover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.</p><p><blockquote>Clover Health由纯粹的嗡嗡声和热情驱动的“迷因”势头似乎已经失去了动力，因为主要讨论板对这个名字的“冷却”。现在，CLOV股票的交易可能会更符合商业基本面。</blockquote></p><p> In that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.</p><p><blockquote>在这方面，该公司在具有数十亿美元潜力的市场中一直是强大的收入来源：Medicare Advantage。第三季度，Clover的收入为4.72亿美元，同比增长153%。然而，该公司距离盈利还有很长的路要走。2021年全年调整后EBITDA预计将分别为负2.5亿美元和2.3亿美元。</blockquote></p><p> One key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.</p><p><blockquote>一个关键问题是，以目前的商业模式，Clover可能需要多长时间才能实现盈利。另一个问题是该公司是否能够在目前的领土之外扩张。这些问题的答案可能会在可预见的未来推动该股的表现。</blockquote></p><p> Lastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.</p><p><blockquote>最后，据华尔街专家称，CLOV股票在目前水平上被低估。尽管该股的普遍评级严重倾向于谨慎，但平均目标价仍为8.67美元，表明该股还有76%的上涨潜力。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Stock Has Slumped. Buy the Dip?<blockquote>三叶草股票暴跌。逢低买入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-03 15:03</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.</p><p><blockquote>过去几个月，Clover Health的股票一直在苦苦挣扎。随着CLOV的“模因”势头消退，股价自6月初的峰值以来已下跌80%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/528f59c934a300195181e1a4f4dda4a0\" tg-width=\"1240\" tg-height=\"698\" width=\"100%\" height=\"auto\"><span>Figure 1: Clover Health logo.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：三叶草健康标志。</span></p></blockquote></p><p> Now, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.</p><p><blockquote>现在，CLOV已触底，股价跌至不到5美元的历史低点。下面，我们列出了一些问题，可以帮助确定现在是否是投资该股票的时候。</blockquote></p><p> <b>The success of Clover Assistant</b></p><p><blockquote><b>三叶草助手的成功</b></blockquote></p><p> AI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.</p><p><blockquote>AI软件平台Clover Assistant是Clover独特模型中的关键差异化因素，它管理着近10万条生命。该平台旨在帮助医生改善服务并吸引新会员。</blockquote></p><p> Clover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.</p><p><blockquote>Clover的商业模式严重依赖于该平台，但专家们对它能否实现其承诺表示怀疑：医生的易用性和患者的省钱机会。Clover Assistant同比增长223%，第三季度约有2,900名医疗保健专业人员使用Clover Assistant，同比增长45%。</blockquote></p><p> <b>Are bears right?</b></p><p><blockquote><b>熊是对的吗？</b></blockquote></p><p> Known as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.</p><p><blockquote>被称为“SPAC之王”的Clover今年早些时候股价暴跌。可能的罪魁祸首：研究公司兴登堡做空该股票，声称该公司因可疑销售行为而成为调查目标。</blockquote></p><p> After Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.</p><p><blockquote>兴登堡下注后，截至5月底，CLOV股价今年迄今暴跌50%。当时，该股引起了华尔街赌注“猿”社区的注意，并成为模因狂热的目标。自6月初以来，股市飙升190%，但随后下跌约80%至历史低点。</blockquote></p><p> Venture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.</p><p><blockquote>帮助Clover通过SPAC上市的风险投资家Chamath Palihapitiya为该公司的指控进行了辩护。但那时，可能已经太晚了：对CLOV的怀疑已经广泛蔓延，该股成为卖空者的最爱。</blockquote></p><p> Currently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.</p><p><blockquote>目前，空头兴趣有点偏热：根据雅虎财经的数据，目前12%的流通量被做空。我们倾向于认为任何高于10%的指标都是看跌指标和潜在的轧空候选指标。</blockquote></p><p> <b>CLOV’s path to profitability</b></p><p><blockquote><b>CLOV的盈利之路</b></blockquote></p><p> Clover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.</p><p><blockquote>Clover Health由纯粹的嗡嗡声和热情驱动的“迷因”势头似乎已经失去了动力，因为主要讨论板对这个名字的“冷却”。现在，CLOV股票的交易可能会更符合商业基本面。</blockquote></p><p> In that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.</p><p><blockquote>在这方面，该公司在具有数十亿美元潜力的市场中一直是强大的收入来源：Medicare Advantage。第三季度，Clover的收入为4.72亿美元，同比增长153%。然而，该公司距离盈利还有很长的路要走。2021年全年调整后EBITDA预计将分别为负2.5亿美元和2.3亿美元。</blockquote></p><p> One key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.</p><p><blockquote>一个关键问题是，以目前的商业模式，Clover可能需要多长时间才能实现盈利。另一个问题是该公司是否能够在目前的领土之外扩张。这些问题的答案可能会在可预见的未来推动该股的表现。</blockquote></p><p> Lastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.</p><p><blockquote>最后，据华尔街专家称，CLOV股票在目前水平上被低估。尽管该股的普遍评级严重倾向于谨慎，但平均目标价仍为8.67美元，表明该股还有76%的上涨潜力。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp"},"source_url":"https://www.thestreet.com/memestocks/clov/clov-stock-has-hit-rock-bottom-time-to-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138290638","content_text":"Clover Health stock has been struggling in the past few months. Shares have reached 80% lower since the early June peak as CLOV’s “meme” momentum faded.\nFigure 1: Clover Health logo.\nNow, CLOV has hit bottom as shares trade at all-time lows of less than $5. Below, we have listed a few questions that could help determine if now is the time to invest in the stock.\nThe success of Clover Assistant\nAI software platform Clover Assistant is the key differentiator in Clover’s unique model, and it has nearly 100,000 lives under management. The platform was designed to help physicians improve their services and attract new members.\nClover’s business model is heavily dependent on the platform, but experts are skeptical as to whether it can deliver what it promises: ease of use for doctors and money saving opportunities for patients. Clover Assistant has grown 223% YOY and approximately 2,900 health care professionals used Clover Assistant in Q3, up 45% YOY.\nAre bears right?\nKnown as the “king of SPACs,” Clover saw its stock price plummet earlier this year. The likely culprit: research firm Hindenburgshortedthe stock, claiming that the company was the target of an investigation for dubious sales practices.\nAfter Hindenburg's bet, CLOV share price plunged 50% year-to-date by the end of May. At that point, the stock caught the attention of Wall Street Bets’ “apes” community and became a target of meme mania. Since early June, stocks spiked 190% but then fell around 80% to all-time lows.\nVenture capitalist Chamath Palihapitiya, who helped Clover go public through SPAC,defended the company from the allegations. But at that point, it may have been too late: skepticism towards CLOV had spread wide and the stock became a short seller favorite.\nCurrently, short interest is a bit on the hot side: 12% of the float is currently shorted,according to Yahoo Finance. We like to think that anything above 10% is a bearish indicator and a potential short squeeze candidate.\nCLOV’s path to profitability\nClover Health’s “meme” momentum driven by sheer buzz and enthusiasm seems to have lost steam as the main discussion boards “cooled down” on the name. Now, CLOV shares could trade more in line with business fundamentals.\nIn that regard, the company has been a strong revenue generator in a market with multi-billion dollar potential: Medicare Advantage. In Q3, Clover generated $472 million in revenues, up an astounding 153% YOY. However, the company is still far from being profitable. Full year 2021 adjusted EBITDA is expected to sit around negative $250 million and $230 million.\nOne key question is how long it may take for Clover to reach profits with the current business model. Another is whether the company will be able to expand outside its current territory. The answers to these questions will likely drive the stock’s performance in the foreseeable future.\nLastly, according to Wall Street experts, CLOV stock is undervalued at current levels. Despite the consensus rating on the stock leaning heavily towards cautious, average price target sits at $8.67, suggesting 76% upside potential from here.","news_type":1,"symbols_score_info":{"CLOV":0.9}},"isVote":1,"tweetType":1,"viewCount":2688,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/601607958"}
精彩评论